Role of Polymorphic Human Cytochrome P450 Enzymes in Estrone Oxidation

Estrogen and its metabolites are believed to play important roles in breast cancer. The influence of genetic polymorphisms in the enzymes responsible for formation and disposition of estrogen on breast cancer risk may shed light on the importance of estrogen metabolites in this disease. However, for such studies to be valid, it is important to correctly identify the enzymes involved in estrogen bioactivation. Therefore, we assessed the human cytochrome P450–dependent oxidation of estrone using substrate concentrations that more closely approximate the maximum expected concentrations in breast tissue. The in vitro metabolism of estrone by recombinant human cytochrome P450 enzymes and human liver microsomes was studied. The formation of estrone metabolites (2-hydroxyestrone, 4-hydroxyestrone, and 16α-hydroxyestrone) was monitored by high-performance liquid chromatography. 2-Hydroxyestrone formation was catalyzed predominantly by CYP1A2, CYP1A1, and CYP1B1 enzymes; 4-hydroxyestrone formation was catalyzed predominantly by CYP1B1, CYP1A2, and CYP1A1 enzymes; and 16α-hydroxyestrone formation was catalyzed predominantly by CYP2C19, CYP1A1, and CYP3A5. This study confirms the important role of members of the CYP1 family in the 2-hydroxylation and 4-hydroxylation of estrone, but the enzymes identified as responsible for the 16α-hydroxylation of estrone are different from those previously identified. The relative importance of these enzymes in vivo would depend on the specific tissue expression of the enzymes. These enzymes are all known to be genetically variant in the human population, and additional studies to assess the role CYP1A2, CYP2C19, and CYP3A5 in breast cancer risk are indicated. (Cancer Epidemiol Biomarkers Prev 2006;15(3):551–8)

[1]  G. Murray,et al.  Immunohistochemical Localization of Cytochrome P450 CYP1B1 in Breast Cancer with Monoclonal Antibodies Specific for CYP1B1 , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  J. Liehr,et al.  Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. , 1997, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[3]  G. Colditz,et al.  Association of CYP1B1 polymorphisms and breast cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  H. Bradlow,et al.  Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Liehr,et al.  Carcinogenicity of catechol estrogens in Syrian hamsters. , 1986, Journal of steroid biochemistry.

[6]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[7]  N. Roodi,et al.  Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. , 1998, Cancer research.

[8]  G. Vollmer,et al.  Catecholestrogens are MCF-7 cell estrogen receptor agonists , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[10]  N. Walker,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Cavalieri,et al.  Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. , 2001, Metabolism: clinical and experimental.

[12]  A. Conney,et al.  Functional role of estrogen metabolism in target cells: review and perspectives. , 1998, Carcinogenesis.

[13]  C. Schneeberger,et al.  Production and actions of estrogens. , 2002, The New England journal of medicine.

[14]  K. Humphreys,et al.  Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. , 2003, Carcinogenesis.

[15]  B. Zhu,et al.  NADPH-dependent metabolism of 17β-estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms , 2005, Steroids.

[16]  M. Gerber,et al.  Interactions between genetic polymorphism of cytochrome P450‐1B1, sulfotransferase 1A1, catechol‐o‐methyltransferase and tobacco exposure in breast cancer risk , 2003, International journal of cancer.

[17]  B. Zumoff Does Postmenopausal Estrogen Administration Increase the Risk of Breast Cancer? Contributions of Animal, Biochemical, and Clinical Investigative Studies to a Resolution of the Controversy , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[18]  J. Lefebvre,et al.  Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation , 1989, Molecular and Cellular Endocrinology.

[19]  A. Conney,et al.  Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. , 2003, Endocrinology.

[20]  J. Bolton,et al.  Role of quinoids in estrogen carcinogenesis. , 1998, Chemical research in toxicology.

[21]  J. Fishman,et al.  Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Kassi,et al.  The oestrogen receptor codon 10 polymorphism detected in breast cancer is also present in non-malignant cells , 1999, Journal of Cancer Research and Clinical Oncology.

[23]  K. Korzekwa,et al.  Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. , 1997, Carcinogenesis.

[24]  A. Conney,et al.  Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol. , 2003, Cancer research.

[25]  J. Wittliff,et al.  Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. , 1989, Journal of steroid biochemistry.

[26]  H. Strobel,et al.  Cytochrome P-450-mediated redox cycling of estrogens. , 1986, The Journal of biological chemistry.

[27]  A. V. Landeghem,et al.  Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. , 1985, Cancer research.

[28]  J. Liehr,et al.  Free radical generation by redox cycling of estrogens. , 1990, Free radical biology & medicine.

[29]  Yager Jd,et al.  Molecular Mechanisms of Estrogen Carcinogenesis , 1996 .

[30]  B. Ponder,et al.  Polymorphisms associated with circulating sex hormone levels in postmenopausal women. , 2005, Journal of the National Cancer Institute.

[31]  A. Conney,et al.  Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. , 2001, The Journal of pharmacology and experimental therapeutics.

[32]  J. Dwyer,et al.  Estrogen metabolism and excretion in Oriental and Caucasian women. , 1994, Journal of the National Cancer Institute.

[33]  L. Horn,et al.  CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes , 2004, British Journal of Cancer.

[34]  J. Sparano,et al.  Urinary estrogen metabolites and breast cancer: a case-control study. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[35]  E. Taioli,et al.  Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. , 1999, Cancer detection and prevention.

[36]  G. Bronte,et al.  Sex Steroids, Carcinogenesis, and Cancer Progression , 2004, Annals of the New York Academy of Sciences.

[37]  W. Busby,et al.  Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[38]  J. Russo,et al.  Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[39]  M. Osborne,et al.  Genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. , 1993, Recent progress in hormone research.

[40]  Y Wang,et al.  Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[41]  F. Guengerich,et al.  16 α-Hydroxylation of estrone by human cytochrome P 4503 A 4 / 5 , 1998 .

[42]  J. Yager,et al.  Molecular mechanisms of estrogen carcinogenesis. , 1996, Annual review of pharmacology and toxicology.

[43]  E. Cavalieri,et al.  A Unifying Mechanism in the Initiation of Cancer and Other Diseases by Catechol Quinones , 2004, Annals of the New York Academy of Sciences.

[44]  X. Shu,et al.  Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection , 2003, Steroids.

[45]  F. Naftolin,et al.  Kinetics of catechol estrogen-estrogen receptor dissociation: A possible factor underlying differences in catechol estrogen biological activity , 1983, Steroids.

[46]  T. Shimada,et al.  Catalytic properties of polymorphic human cytochrome P450 1B1 variants. , 1999, Carcinogenesis.

[47]  O. Pelkonen,et al.  The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue , 2001, Breast Cancer Research and Treatment.

[48]  I. Roots,et al.  Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. , 2005, Cancer research.

[49]  I. Helenowski,et al.  Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[50]  L. Kuller,et al.  Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. , 1998, British Journal of Cancer.

[51]  A. D. Rodrigues,et al.  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. , 1999, Biochemical pharmacology.

[52]  C. Martucci,et al.  P450 enzymes of estrogen metabolism. , 1993, Pharmacology & therapeutics.

[53]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[54]  David Bouwman,et al.  Cytochrome p450 and glutathione transferase expression in human breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  H. Yamazaki,et al.  Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. , 1998, Chemical research in toxicology.

[56]  R. Edwards,et al.  Expression of CYP3A4 in human breast tumour and non-tumour tissues. , 2003, Cancer letters.

[57]  Francesmary Modugno,et al.  A Potential Role for the Estrogen-metabolizing Cytochrome P450 Enzymes in Human Breast Carcinogenesis , 2003, Breast Cancer Research and Treatment.

[58]  E. Taioli,et al.  A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. , 1995, Cancer research.

[59]  A. Harris,et al.  Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. , 1990, Carcinogenesis.

[60]  I. Helenowski,et al.  Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. , 2005, The Journal of clinical endocrinology and metabolism.

[61]  J. Fishman Aromatic hydroxylation of estrogens. , 1983, Annual review of physiology.

[62]  J. Liehr Genotoxic effects of estrogens. , 1990, Mutation research.

[63]  N. Chauret,et al.  Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[64]  F. Guengerich,et al.  16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. , 1998, Carcinogenesis.

[65]  J. Seegers,et al.  Effects of 17β-Estradiol Metabolites on Cell Cycle Events in MCF-7 Cells , 1992 .

[66]  M. Osborne,et al.  2-hydroxyestrone: the 'good' estrogen. , 1996, The Journal of endocrinology.

[67]  K. Anderson,et al.  Abnormal oxidative metabolism of estradiol in women with breast cancer. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Osborne,et al.  Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. , 1992, Journal of the National Cancer Institute.

[69]  D. Spandidos,et al.  Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer. , 2001, International journal of molecular medicine.

[70]  A. Hirvonen,et al.  Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. , 2003, Mutation research.